Why do headline vet clinic sale prices not match what my practice is worth?
Headline vet clinic sale prices come from platform-level private equity transactions, not single-clinic sales, so they are not a benchmark for what an individual practice is worth. EQT's roughly $1.4bn acquisition of VetPartners in 2023, and TPG's earlier roll-up and partial sell-down of Greencross, are the price paid for control of a national network of 150-270+ clinics, specialty hospitals and the management infrastructure that runs them — reported in the media as "vet clinic multiples" but not comparable to what a single suburban or regional practice sells for. A platform earns a scale premium that an individual clinic, sold on its own, does not receive. Confusing the two is the most common valuation error vet owners bring to an engagement — usually from a broker's marketing material or a headline, not from evidence.
What multiple of EBITDA do vet clinics sell for in Australia?
For single-clinic and small-group transactions in Australia, working multiple ranges vary sharply with how dependent the practice is on the owner-vet, from roughly 2.5x EBITDA for a solo owner-treated practice to 5.5x-8x for a multi-vet, associate-driven clinic a consolidator is genuinely competing for:
- ·Solo practitioner, owner is the primary consulting vet: roughly 2.5x–4x EBITDA. Most of the goodwill is personal, so most buyers price it closer to an asset-plus-client-list transaction than a business acquisition.
- ·Small-to-mid practice, 2–4 vets with some associate coverage: roughly 4x–6x EBITDA. Earnings are partly transferable, so the multiple reflects a blended personal/enterprise goodwill position.
- ·Multi-vet, associate-driven practice with the owner in a management (not primary clinical) role: roughly 5.5x–8x EBITDA, and toward the top of that band where a corporate consolidator is genuinely competing for the asset.
- ·Corporate consolidator platform-level acquisitions (rolling up many clinics under one PE-backed group): can run into the low double digits at the platform level, but this is a price for scale and infrastructure, not a per-clinic benchmark.
Why do corporate consolidators pay more than a private buyer would?
Corporate consolidators pay more because they are buying a marginal addition to a portfolio, not a single clinic's earnings on their own — centralised procurement, shared locum and support-staff pools, existing back-office systems and multi-site referral networks let a group extract synergies an individual buyer cannot. That synergy value is real, but under the market value standard applied in IVS 104 it belongs to the acquirer's structure, not to the clinic being sold, which is why methodology matters: a valuation prepared for a CGT event, a shareholder exit or a Family Court matter should be built on what a market participant without those group-level synergies would pay, unless there is specific, current evidence that a corporate buyer is actively in the market for that particular clinic. Assuming a consolidator-level multiple because a broker mentioned one in an appraisal, without evidence of genuine current interest from a scale buyer, is exactly the kind of unsupported position that does not survive scrutiny.
Does the vet shortage affect what my clinic is worth?
Yes: practitioner supply, not pet ownership or clinical demand, is the binding constraint on Australian vet clinic earnings, and it is a direct input into the multiple. Veterinarians have sat on the National Skills Priority List for several years and average time to fill a vacant role has stretched well beyond the historical norm, with regional roles taking materially longer than metropolitan ones. That shortage has a direct valuation consequence: a clinic's revenue ceiling is set by how many consulting hours it can staff, not by how many appointments it could theoretically book. A clinic already running near practitioner capacity has a genuine constraint on organic earnings growth that a buyer will price in — either as a lower multiple (growth requires a hire that may not be findable) or as a specific adjustment for locum reliance, unfilled roles, or associate turnover risk. Conversely, a clinic with spare consulting capacity and a credible plan to fill it is a different earnings trajectory, and the valuation should say so with evidence — rostered hours, vacancy history, and the realistic timeframe to recruit — not with an optimistic forecast.
Does personal goodwill or clinic goodwill make the biggest difference to the multiple?
Whether the goodwill transfers with the sale or walks out the door with the owner is the single biggest driver of the multiple, and the factor tested hardest in every credible vet clinic engagement. Where clients are loyal to a named treating vet rather than to the clinic's brand, systems and booking process, a buyer is acquiring a client list with an uncertain retention curve, not a transferable earnings stream — and the multiple compresses accordingly. Evidence that supports enterprise (transferable) goodwill includes: consult bookings spread across multiple vets rather than concentrated on the owner; a practice management system with client records, recall reminders and standard treatment protocols independent of any one clinician; branded signage, marketing and online reviews attached to the clinic rather than an individual; and a demonstrated retention rate through prior associate departures or locum cover. Evidence that points the other way — genuine personal goodwill — includes an owner who performs the large majority of consults personally, informal or undocumented client relationships, and no tested precedent for client retention when the owner is absent. A valuation that does not test this distinction with clinic-specific evidence, and instead applies a market-average multiple regardless of ownership structure, is not a supportable position under APES 225.
Does revenue mix change what a vet clinic is worth?
Yes: two vet clinics with identical revenue can have very different quality of earnings depending on the mix behind the top line, because a maintainable earnings assessment weights recurring, low-risk revenue more heavily than discretionary or key-person-dependent revenue. Consults and core clinical work (vaccinations, health checks, chronic disease management) are the most recurring and least discretionary revenue line, and typically the most heavily weighted. Surgery and procedural revenue is higher-margin but more dependent on specific practitioner skill sets and equipment — a clinic reliant on one surgically capable vet has a key-person exposure that a multi-vet, cross-trained team does not. Retail (pet food, parasiticides, prescription diets) carries lower margin and faces increasing price competition from online and pet-superstore retailers, so a revenue mix heavily skewed to retail is generally viewed as lower quality than one anchored in clinical services. Grooming and boarding, where offered, are typically treated as a separate, lower-multiple ancillary revenue stream unless they are integrated enough with the clinical business to share overhead and cross-referral in a way the evidence can demonstrate. A defensible valuation disaggregates the revenue mix and weights the methodology accordingly, rather than applying one blended multiple to an undifferentiated total.
What do corporate consolidators actually screen for before buying a vet clinic?
Not every clinic is a realistic candidate for a consolidator-level multiple, regardless of how a broker frames the opportunity. From publicly available acquisition criteria and market commentary, the recurring screening factors are: scale (revenue and EBITDA thresholds that make the transaction worth the group's transaction and integration cost — a very small solo practice is rarely a standalone target); an associate-led or at least associate-capable clinical model, so the group is not dependent on the vendor staying on indefinitely; facility standard (modern fit-out, adequate equipment, imaging and surgical capability, and compliance with current practice accreditation standards) since bringing a substandard site up to group standard is a cost the acquirer will price into the offer; lease tenure and terms (a short remaining lease, an unfavourable rent review structure, or a landlord unwilling to assign or extend is a common deal-breaker or price reducer, since the group is acquiring a location as much as a business); and a metropolitan or larger regional-centre location with a stable or growing local pet-owning population, rather than a thin rural catchment. A clinic that fails several of these screens may still be a good, profitable business — it is simply more likely to be bought by another vet or a small independent operator at the lower end of the range than by a scale acquirer at the top.
Do I need a formal valuation to sell a vet clinic or claim CGT concessions?
A formal valuation is not a legal requirement to sell a vet clinic, but it becomes necessary wherever a tax position, a related-party transaction or a disputed price needs evidence behind it. Small business CGT concession claims under Division 152 of the ITAA 1997 turn on the maximum net asset value test — net CGT assets of the taxpayer, connected entities and affiliates no more than $6m just before the CGT event — and the active asset test, so the valuation evidence sits underneath your accountant's eligibility position, not in place of it. Where the transfer is not at arm's length, market value substitution under s 116-30 can apply. For CGT events, small business CGT concession claims, shareholder or partnership exits, and Family Court matters, the methodology question is which market the clinic actually sells into — not which market the owner hopes it sells into. Capitalisation of Maintainable Earnings, cross-checked against genuinely comparable transaction evidence for clinics of similar scale, staffing model and location, is typically the primary methodology, with Net Asset Value serving as a floor check where fit-out and equipment are material. Prismi prepares the valuation with the ATO's market valuation guidance and APES 225 in mind; we are not a registered tax agent and do not provide tax, legal or financial advice, so your accountant applies the tax outcome and confirms concession eligibility. Where a consolidator-level multiple is asserted, the evidence has to support it specifically — a documented approach from a corporate buyer, comparable completed transactions for clinics of a similar profile, or a credible engagement process — not the general proposition that "corporates are buying vet clinics." Where the evidence only supports an independent-buyer multiple, that is the most supportable position, even where a higher number would be more welcome.
What does a vet clinic valuation cost and how long does it take?
Prismi prices a vet clinic valuation by tier: the Essential report from $1,495 + GST (10–14 business days) suits early-stage planning where an indicative view is enough; the Comprehensive report from $3,995 + GST (15–25 business days) is typically the right fit for a clinic sale, associate buy-in or restructure, with full methodology and the market-access finding documented; and the Defensible Valuation File from $8,995 + GST (25–35 business days) is the level a consolidator negotiation, a small business CGT concession claim, or a review-likely matter warrants. Retrospective valuation dates attract a $495 surcharge per historical date, additional entities (common where a service trust or freehold entity sits beside the clinic) are $750 each, and rush delivery is +30% of the base fee subject to capacity. Fees are fixed at engagement and never contingent on the outcome.